| Patient | George H. W. Bush |
|---|---|
| Date of birth | 1959-06-12 |
| Identifiers | MRN HR-ML018-SYN; SSN (made up) 000-18-7245 |
| Document date | 2026-09-11 |
| Author | Douglas Whitford, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Four-month review: levothyroxine dose and the anticoagulation decision. [S]
Mr. Bush returns eight weeks after starting levothyroxine 75 mcg daily. His tiredness and constipation are better, and he feels cold only occasionally. He took metoprolol 25 mg daily for eight weeks and finished the taper this week. He wore the 14-day ECG patch for the two weeks ending four days ago, with no palpitations. He takes apixaban twice daily with no bleeding. He runs three miles four days a week without symptoms and has regained his usual weight. He takes levothyroxine alone on an empty stomach each morning. [S]
| Element | Detail |
|---|---|
| Thyroid symptoms | Tiredness and constipation better; occasionally cold |
| Rhythm | No palpitations; 14-day patch completed |
| Medicines | Levothyroxine 75 mcg daily; metoprolol taper completed; apixaban twice daily |
| Activity | Running three miles four days a week |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Occasionally cold; energy nearly back to normal; weight back to his usual |
| Cardiovascular | Negative | No palpitations, chest pain, or lightheadedness |
| Gastrointestinal | Negative | Bowels regular |
| Hematologic | Negative | No bleeding or bruising |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metoprolol succinate extended-release 50 mg oral tablet, one tablet by mouth daily (started in hospital) | One tablet each morning | Oral route | 2026-05-05 to 2026-07-17 | stopped | S |
| Metoprolol succinate extended-release 25 mg oral tablet, one tablet by mouth daily (taper) | One tablet each morning for eight weeks, then stop | Oral route | 2026-07-17 to 2026-09-11 | stopped | S |
| Apixaban 5 mg oral tablet, one tablet by mouth twice daily (started in hospital) | One tablet twice daily | Oral route | 2026-05-05 to 2026-09-11 | stopped | S |
| Methimazole 10 mg oral tablet, two tablets (20 mg) by mouth daily | Two tablets once daily; stop three days before radioactive iodine | Oral route | 2026-05-08 to 2026-05-26 | completed | S |
| Levothyroxine 75 mcg oral tablet, one tablet by mouth daily before breakfast | One tablet on an empty stomach 30 to 60 minutes before breakfast | Oral route | 2026-07-17 to 2026-09-11 | stopped | S |
| Levothyroxine 100 mcg oral tablet, one tablet by mouth daily before breakfast | One tablet on an empty stomach 30 to 60 minutes before breakfast | Oral route | 2026-09-11 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-09-11 | Body height | 188 | cm | S |
| 2026-09-11 | Body weight | 90.2 | kg | S |
| 2026-09-11 | Body mass index (BMI) [Ratio] | 25.5 | kg/m2 | S |
| 2026-09-11 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-09-11 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-09-11 | Heart rate | 62 | /min | S |
| 2026-09-11 | Respiratory rate | 14 | /min | S |
| 2026-09-11 | Body temperature | 36.6 | Cel | S |
| 2026-09-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-09-11 | Thyrotropin [Units/volume] in Serum or Plasma | 6.4 | m[IU]/L | 0.4-4 mIU/L | High | S |
| 2026-09-11 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 0.9 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
Vital signs recorded on 2026-09-11; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well and fit |
| Neck | Small, non-tender thyroid |
| Cardiovascular | Regular rhythm at 62 per minute; no murmur |
| Neurological | Reflexes normal |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Paroxysmal atrial fibrillation, first detected four days before intake while running, triggered by hyperthyroidism; CHA2DS2-VASc 1; synthetic modern episode linked to his documented atrial fibrillation | active | confirmed | I48.0 | S — Synthetic modern classification of a documented arrhythmia. |
| Graves' disease with hyperthyroidism; synthetic modern diagnosis linked to his documented Graves' disease | active | confirmed | E05.00 | S — Synthetic modern diagnosis confirmed by thyroid tests and TSH receptor antibody; the historical diagnosis is D. |
| Hypothyroidism after radioactive iodine, on levothyroxine replacement | active | confirmed | E89.0 | S — Synthetic modern diagnosis linked to his documented hypothyroidism and lifelong thyroid hormone. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Heart rate and rhythm | Every visit | Completed today | 62 per minute, regular, off metoprolol |
| Examination | Blood pressure | Every visit; target below 130/80 | Completed today | 126/76 mmHg |
| Examination | Weight and BMI | Every visit | Completed today | 90.2 kg, BMI 25.5; back to his usual weight |
| Survey | Atrial fibrillation symptoms | Every visit | Completed today | None |
| Imaging | Ambulatory rhythm monitoring | As symptoms or decisions require | Completed today | 14-day ECG patch: sinus rhythm throughout; no atrial fibrillation or flutter |
| Survey | CHA2DS2-VASc and HAS-BLED | Yearly and with any change in clinical status | Completed today | Reassessed for the anticoagulation decision: CHA2DS2-VASc 1, HAS-BLED 1 |
| Medication safety | Anticoagulation decision | With any change in clinical status | Completed today | Apixaban stopped by shared decision after sustained sinus rhythm with the trigger treated |
| Laboratory | Creatinine and eGFR on apixaban | At baseline and at least yearly | Not indicated | Apixaban stopped today |
| Self-management | Alcohol, tobacco, and physical activity | Every visit | Completed today | Alcohol rarely; never used tobacco; running about 200 minutes a week |
| Survey | Sleep apnea symptom screen | At diagnosis and at least yearly | Up to date | Negative two months ago |
| Laboratory | TSH after a levothyroxine dose change | Four to eight weeks after each dose change | Completed today | TSH 6.4 mIU/L, free T4 0.9 ng/dL, eight weeks after starting 75 mcg |
| Survey | Hypothyroid and overtreatment symptoms | Every visit during titration | Completed today | Mild residual cold intolerance; no palpitations, tremor, or weight loss |
| Laboratory | TSH at six months once stable, then yearly | After the dose is stable | Due | Dose changed today; TSH in six weeks first |
Goal progress:
Guideline basis: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement (2014); CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026)
Follow-up: TSH in six weeks; annual wellness visit next month. Next scheduled visit 2026-10-16: subsequent annual wellness visit. [S]